Trending Now
AVEO Oncology (NASDAQ:AVEO) Announce Publication Of Phase 3 TIVO-3 Study Data...
AVEO Oncology (NASDAQ:AVEO) has announced the final overall survival data from the Phase 3 TIVO-3 Study in the European Urology journal.
AVEO publishes TIVI-3 study...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
VectivBio Holding AG (NASDAQ: VECT) Makes Agreement with Kreos Capital and...
VectivBio Holding AG (NASDAQ: VECT) has made two deals that would benefit its operations, balance sheets, and expand the commercialization of apraglutide away from...
MAKE IT MODERN
LATEST REVIEWS
Travere Therapeutics Inc. (NASDAQ: TVTX) Submits New Drug Application For Sparsentan...
Travere Therapeutics Inc. (NASDAQ: TVTX) has submitted a New Drug Application to the FDA for accelerated clearance for sparsentan under Subpart h for IgA...
MAKE IT MODERN
PERFORMANCE TRAINING
Baudax Bio Inc. (NASDAQ:BXRX) Strikes a Group Purchasing Agreement with Premier Inc.
Baudax Bio Inc. (NASDAQ:BXRX) works with patients, health care providers, and payers the likes of ANJESO® (meloxicam) injection. The company's focus is predominantly on...
Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) Announce Positive Results For IV Ampion Treatment In Hospitalized COVID-19...
Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) has announced positive results in the initial intravenous Ampion™ treatment trial in COVID-19 patients.
Ampio’s lead drug shows potential in the...
Nabriva’s (NASDAQ:NBRV) XELENTA Shows Efficacy In Treating Community-Acquired Bacterial Pneumonia Patients Above 65 Years
Nabriva Therapeutics plc (NASDAQ:NBRV) has announced that XELENTA (lefamulin ) has shown significant efficacy in a posthoc analysis of LEAP 1and LEAP Phase 3...
Monopar Therapeutics’ (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial
Exciting news from the world of cancer research! Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharma company, has just released positive early data...
Stock Futures Rise Ahead Of Inflation Data (PEP, JPM, DAL, MGRX)
May 18, 2023. Since then, MGRX has been on a roll to promote its flagship product. For more info on MGRX, visit...
MAKE IT MODERN
